Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1555-2015Class IITerminatedSep 23, 2015Hydromorphone 65 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1554-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Bupivacaine 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1553-2015Class IITerminatedSep 23, 2015Hydromorphone 5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1552-2015Class IITerminatedSep 23, 2015Hydromorphone 40 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1551-2015Class IITerminatedSep 23, 2015Hydromorphone 40 mg/ml + Bupivacaine 20 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1550-2015Class IITerminatedSep 23, 2015Hydromorphone 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1549-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml + Bupivacaine 0.25 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1548-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1547-2015Class IITerminatedSep 23, 2015Hydromorphone 15 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1546-2015Class IITerminatedSep 23, 2015Hydromorphone 12.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1545-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml + Bupivacaine 10 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1544-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml + Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1543-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1542-2015Class IITerminatedSep 23, 2015Hydromorphone 1 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1541-2015Class IITerminatedSep 23, 2015Hydromorphone 0.25 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1540-2015Class IITerminatedSep 23, 2015Hyaluronidase 175 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1539-2015Class IITerminatedSep 23, 2015Hyaluronidase 150 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1538-2015Class IITerminatedSep 23, 2015Hyaluronidase 150 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1537-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 35 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1536-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 32 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1535-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 28 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1534-2015Class IITerminatedSep 23, 2015HCG 500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1533-2015Class IITerminatedSep 23, 2015HCG 1,200 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1532-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1531-2015Class IITerminatedSep 23, 2015HCG 4,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1530-2015Class IITerminatedSep 23, 2015HCG 3,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1529-2015Class IITerminatedSep 23, 2015HCG 2,500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1528-2015Class IITerminatedSep 23, 2015HCG 1,100 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1527-2015Class IITerminatedSep 23, 2015HCG 1,500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1526-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1525-2015Class IITerminatedSep 23, 2015HCG 11,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1524-2015Class IITerminatedSep 23, 2015HCG 1,250 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1523-2015Class IITerminatedSep 23, 2015HCG 625 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1522-2015Class IITerminatedSep 23, 2015HCG 2,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1521-2015Class IITerminatedSep 23, 2015HCG 10,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1520-2015Class IITerminatedSep 23, 2015HCG 1,100 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1519-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1518-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml + Methylcobalamin 500 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1517-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml + Methylcobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1516-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.